CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Biotechnology

Healthcare
$4.00 +2.42%

+$0.10 today

Market cap
$251.02M
Beta
0.08
P/E (TTM)
-2.8
EPS (TTM)
-$1.49
52W Low $1.31High $7.75

Volume 0.21M

Average 0.10M

Returns on capital

CAMP4 Therapeutics Corporation management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-168.5%

avg -22.6%

ROIC

-50.8%

avg -24.8%

ROA

-68.2%

avg -26.0%

Analysis

ROIC is currently the strongest return metric at -50.8% versus its period average of -24.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Joshua Mandel-Brehm

Chief Executive Officer, President & DirectorUSD 896.25K43——

Kelly Gold

Chief Financial OfficerUSD 734.69K4910.00K0.05%

Yuri Maricich

Chief Medical OfficerUSD 702K4512.61K0.06%

Richard A. Young

Founder & Independent DirectorUSD 146.56K72186.39K0.88%

Daniel Tardiff

Chief Scientific Officer—460<0.01%

Leonard I. Zon

Founder & Chairman of Scientific Advisory Board————

Caleb Moore

Chief Business Operations Officer————

Alla Sigova

Senior Vice President of Platform————

Michelle Gates

Senior Vice President & Chief People Officer————

Satya Kuchimanchi

Senior Vice President of Technical Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 31, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

6

$99,369.11

Sells

6

$2.50M

Net Transaction Value

−$2.40M

Net selling

Most Active

Schwab Andrew J.

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 31, 26

Gold Kelly

Indirect

Buy$39.6K
Aug 27, 26

Schwab Andrew J.

Indirect

Sell$1.6M
Aug 24, 26

Schwab Andrew J.

Indirect

Sell$45
Aug 21, 26

Schwab Andrew J.

Indirect

Sell$144.1K
Aug 20, 26

Schwab Andrew J.

Indirect

Sell$520.7K
Aug 19, 26

Tardiff Daniel

Direct

Sell$8.3K
Aug 19, 26

Schwab Andrew J.

Indirect

Sell$214.9K
Aug 3, 26

5AM Partners VI, LLC

Indirect

Buy$318
Aug 3, 26

Young Richard A

Direct

Buy$27K
Aug 3, 26

Maricich Yuri

Direct

Buy$10.8K

1–10 of 12

Summary

Insiders reported 6 buys worth $99,369.11 and 6 sells worth $2.50M over the last 12 months. That adds up to net selling of $2.40M. Schwab Andrew J. was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
+35.4% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Forward estimates point to Revenue at +35.4% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does CAMP4 Therapeutics Corporation compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CAMP's management, answered from reported figures.

Who manages CAMP?

CAMP4 Therapeutics Corporation (CAMP) lists 10 active executives. The top listed executive is Daniel Tardiff, Chief Scientific Officer.

Are CAMP insiders buying or selling?

Recent insider activity shows net buying of $95.67M.